Dr. Bizzell Speaks About the First FDA-Approved Treatment for Ebola

Dr. Anton C. Bizzell shares his insights in the Verywell Health article, “Regeneron Earns First-Ever FDA Approval For Ebola Treatment,” about the U.S. Food and Drug Administration (FDA) approval of Inmazeb, an antibody cocktail designed to treat the Ebola virus. A mixture of three monoclonal antibodies administered via injection is the first FDA-approved treatment for the virus. The drug is manufactured by Regeneron, the same company behind the antibody cocktail aimed at treating COVID-19. The Bizzell Group (Bizzell) has been on the ground fighting the Ebola virus in the Democratic Republic of Congo. “The approval of Inmazeb is not only a big deal, it is the approach to prevent a future Ebola pandemic worldwide,” Dr. Bizzell tells Verywell.

READ MORE: Regeneron Earns First-Ever FDA Approval For Ebola Treatment

Lessons for COVID-19 Recovery From the Ebola Epidemic

Lessons for COVID-19 Recovery From the Ebola Epidemic

In a recent Psychology Today article, Dr. Anton C. Bizzell highlights some of the lessons The Bizzell Group (Bizzell) learned during the most recent Ebola virus epidemic. Bizzell partnered with local, national, and international groups to improve health outcomes and mental health consequences in the Democratic Republic of Congo. These lessons can help address the global mental health crisis already emerging due to COVID-19.
“We cannot focus solely on the transmission of COVID-19,” Dr. Bizzell writes. “We must formulate an innovative and sustainable response that addresses the global mental health crisis already emerging.”

READ MORE: Lessons for COVID-19 Recovery From the Ebola Epidemic